Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2018; 17: 133-135
Жидкостные биопсии в детской нейроонкологии: в преддверии возможностей тераностики
https://doi.org/10.24287/1726-1708-2018-17-1-133-135Аннотация
Список литературы
1. Taylor M.D., Northcott P.A. Korshunov A., Remke M., Cho Y.J., Clifford S.C., et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol 2012 Apr; 123 (4): 465-72.
2. Pajtler K.W., Mack S.C., Ramaswamy V., Smith C.A., Witt H., Smith A., et al. The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. Acta Neuropathol 2017 Jan; 133 (1): 5.
3. Sturm D., Pfister S.M., Jones D.T.W. Pediatric Gliomas: Current Concepts on Diagnosis, Biology, and Clinical Management. J Clin Oncol 2017 Jul 20; 35 (21): 2370-7.
4. Louis D.N., Perry A., Reifenberger G., von Deimling A., Figarella-Branger D., Cavenee W.K., et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 2016 Jun; 131 (6): 803-20.
5. Gupta A., Dwivedi T. A Simplified Overview of World Health Organization Classification Update of Central Nervous System Tumors 2016. J Neurosci Rural Pract 2017 Oct-Dec; 8 (4): 629-41.
6. Lopez G.Y., Oberheim Bush N.A., Phillips J.J., Bouffard J.P., Moshel Y.A., Jaeckle K. Diffuse midline gliomas with subclonal H3F3A K27M mutation and mosaic H3.3 K27M mutant protein expression. Acta Neuropathol 2017 Dec; 134 (6): 961-3.
7. Wesseling P., Capper D. WHO 2016 Classification of Gliomas. Neuropathol Appl Neurobiol 2017 Aug; 16.
8. Connolly I.D., Li Y., Gephart M.H., Nagpal S. The "Liquid Biopsy": the Role of Circulating DNA and RNA in Central Nervous System Tumors. Curr Neurol Neurosci Rep 2016 Mar; 16 (3): 25.
9. Hanahan D.,Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011 Mar 4; 144 (5): 646-74.
10. Benesova L., Belsanova B., Suchanek S., Kopeckova M., Minarikova P., Lipska L., et al. Mutation-based detection and monitoring of cell-free tumor DNA in peripheral blood of cancer patients. Anal Biochem 2013; 433: 227-34.
11. Diaz L.A., Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 2014 Feb 20; 32 (6): 579-86.
12. Huang T.Y., Piunti A., Lulla R.R., Qi J., Horbinski C.M., Tomita T., et al. Detection of Histone H3 mutations in cerebrospinal fluid-derived tumor DNA from children with diffuse midline glioma. Acta Neuropathol Commun 2017 Apr 17; 5 (1): 28.
13. Dawson S.J., Tsui D.W., Murtaza M., et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 2013; 368: 1199-209.
14. Delgado P.O., Alves B.C., Gehrke Fde S. Characterization of cell-free circulating DNA in plasma in patients with prostate cancer. Tumour Biol 2013; 34: 983-6.
15. Hashad D., Sorour A., Ghazal A. Free circulating tumor DNA as a diagnostic marker for breast cancer. J Clin Lab Anal 2012; 26: 467-72.
16. Taniguchi K., Uchida J., Nishino K. Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas. Clin Cancer Res 2011; 17: 7808-15.
17. Sozzi G., Boeri M. Potential biomarkers for lung cancer screening. Transl lung cancer Res 2014; 3: 139-48.
18. Zaporozhchenko I.A., Ponomaryova A.A., Rykova E.Y., Laktionov P.P. The potential of circulating cell-free RNA as cancer biomarker: challenges and opportunities. Expert Rev Mol Diagn 2018 Jan; 15: 1-13.
19. Nikbakht H., Panditharatna E., Mikael L.G., Li R., Gayden T., Osmond M., et al. Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma. Nat Commun 2016 Apr 6; 7: 11185.
20. Armengol C., Cairo S. Identification of theranostic biomarkers to improve the stratification of patients with pediatric liver cancer: Opportunities and challenges. Hepatology 2018 Jan 12.
21. Peneta M., Chena Z., Kakkada S., Pompera M.G., Bhujwallaa Z.M. Theranostic imaging of cancer. Eur J Radiol 2012 Sep; 81 (01): S124-S126.
22. Ghorbani M., Bigdeli B., Jalili-Baleh L., Baharifar H., Akrami M., Dehghani S. Curcumin-lipoic acid conjugate as a promising anticancer agent on the surface of gold iron oxide nanocomposites: A pH-sensitive targeted drug delivery system for brain cancer theranostics. Eur J Pharm Sci 2017 Dec 14; 114: 175-88.
Pediatric Hematology/Oncology and Immunopathology. 2018; 17: 133-135
Liquid Biopsy in Pediatric Brain Cancers: A Theragnostic Opportunity
https://doi.org/10.24287/1726-1708-2018-17-1-133-135Abstract
Pediatric brain tumors are amongst the most challenging childhood cancers. This challenge is posed by tumor’s sensitive anatomical location, relative rapid progression, and lack of sensitive disease monitoring system. Current tumor diagnostic and monitoring including MR imaging often lack sensitivity, fail to detect early recurrence, and requires general anesthesia when used for in young children. Liquid biopsy, where serum, plasma or cerebrospinal fluid (CSF) is used for detection of circulating tumor DNA (ctDNA) is emerging as a platform for therapeutic and diagnostic (theragnostic) tumor monitoring. Liquid biopsy provides a non-to-minimally invasive method that is sensitive, specific, cost effective approach for monitoring tumor growth, relapse and response to treatment. In this review, we will discuss liquid biopsy, and its current use and its potential for theragnostic use in childhood CNS malignancies.
References
1. Taylor M.D., Northcott P.A. Korshunov A., Remke M., Cho Y.J., Clifford S.C., et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol 2012 Apr; 123 (4): 465-72.
2. Pajtler K.W., Mack S.C., Ramaswamy V., Smith C.A., Witt H., Smith A., et al. The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. Acta Neuropathol 2017 Jan; 133 (1): 5.
3. Sturm D., Pfister S.M., Jones D.T.W. Pediatric Gliomas: Current Concepts on Diagnosis, Biology, and Clinical Management. J Clin Oncol 2017 Jul 20; 35 (21): 2370-7.
4. Louis D.N., Perry A., Reifenberger G., von Deimling A., Figarella-Branger D., Cavenee W.K., et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 2016 Jun; 131 (6): 803-20.
5. Gupta A., Dwivedi T. A Simplified Overview of World Health Organization Classification Update of Central Nervous System Tumors 2016. J Neurosci Rural Pract 2017 Oct-Dec; 8 (4): 629-41.
6. Lopez G.Y., Oberheim Bush N.A., Phillips J.J., Bouffard J.P., Moshel Y.A., Jaeckle K. Diffuse midline gliomas with subclonal H3F3A K27M mutation and mosaic H3.3 K27M mutant protein expression. Acta Neuropathol 2017 Dec; 134 (6): 961-3.
7. Wesseling P., Capper D. WHO 2016 Classification of Gliomas. Neuropathol Appl Neurobiol 2017 Aug; 16.
8. Connolly I.D., Li Y., Gephart M.H., Nagpal S. The "Liquid Biopsy": the Role of Circulating DNA and RNA in Central Nervous System Tumors. Curr Neurol Neurosci Rep 2016 Mar; 16 (3): 25.
9. Hanahan D.,Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011 Mar 4; 144 (5): 646-74.
10. Benesova L., Belsanova B., Suchanek S., Kopeckova M., Minarikova P., Lipska L., et al. Mutation-based detection and monitoring of cell-free tumor DNA in peripheral blood of cancer patients. Anal Biochem 2013; 433: 227-34.
11. Diaz L.A., Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 2014 Feb 20; 32 (6): 579-86.
12. Huang T.Y., Piunti A., Lulla R.R., Qi J., Horbinski C.M., Tomita T., et al. Detection of Histone H3 mutations in cerebrospinal fluid-derived tumor DNA from children with diffuse midline glioma. Acta Neuropathol Commun 2017 Apr 17; 5 (1): 28.
13. Dawson S.J., Tsui D.W., Murtaza M., et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 2013; 368: 1199-209.
14. Delgado P.O., Alves B.C., Gehrke Fde S. Characterization of cell-free circulating DNA in plasma in patients with prostate cancer. Tumour Biol 2013; 34: 983-6.
15. Hashad D., Sorour A., Ghazal A. Free circulating tumor DNA as a diagnostic marker for breast cancer. J Clin Lab Anal 2012; 26: 467-72.
16. Taniguchi K., Uchida J., Nishino K. Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas. Clin Cancer Res 2011; 17: 7808-15.
17. Sozzi G., Boeri M. Potential biomarkers for lung cancer screening. Transl lung cancer Res 2014; 3: 139-48.
18. Zaporozhchenko I.A., Ponomaryova A.A., Rykova E.Y., Laktionov P.P. The potential of circulating cell-free RNA as cancer biomarker: challenges and opportunities. Expert Rev Mol Diagn 2018 Jan; 15: 1-13.
19. Nikbakht H., Panditharatna E., Mikael L.G., Li R., Gayden T., Osmond M., et al. Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma. Nat Commun 2016 Apr 6; 7: 11185.
20. Armengol C., Cairo S. Identification of theranostic biomarkers to improve the stratification of patients with pediatric liver cancer: Opportunities and challenges. Hepatology 2018 Jan 12.
21. Peneta M., Chena Z., Kakkada S., Pompera M.G., Bhujwallaa Z.M. Theranostic imaging of cancer. Eur J Radiol 2012 Sep; 81 (01): S124-S126.
22. Ghorbani M., Bigdeli B., Jalili-Baleh L., Baharifar H., Akrami M., Dehghani S. Curcumin-lipoic acid conjugate as a promising anticancer agent on the surface of gold iron oxide nanocomposites: A pH-sensitive targeted drug delivery system for brain cancer theranostics. Eur J Pharm Sci 2017 Dec 14; 114: 175-88.
